RESUMEN
The proposed metabolic advantage of 6-thioguanine (6-TG) is the direct conversion into the pharmacologically active 6-thioguaninenucleotides (6-TGN). The authors assessed metabolic characteristics of 6-TG treatment in patients with Crohn's disease (N = 7) on therapy with 20 mg 6-TG. 6-thioguanine-monophosphate (6-TGMP), 6-thioguanine-diphosphate (6-TGDP), and 6-thioguanine-triphosphate (6-TGTP) were measured by high-performance liquid chromatography analysis in erythrocytes. Thiopurine S-methyltransferase activity and total 6-TGN levels were determined by standard methods. High interindividual variance in metabolite measurements was observed. Main metabolites were 6-TGTP (median = 531 pmol/8 x 10(8) red blood cells) and 6-TGDP (median = 199 pmol/8 x 10(8) red blood cells). Traces of 6-TGMP (median = 39 pmol/8 x 10(8) red blood cells) and 6-TG (2 patients) could be detected. 6-TGN levels correlated with 6-TGTP levels (r = 0.929, P = .003) and with the sum of separate nucleotides (r = 0.929, P = .003). No correlations were established between TPMT activity (median = 13 pmol/h/10(7)) and 6-TG metabolites. The 1-step metabolism of 6-TG still leads to high interindividual variance in metabolite concentrations. Total 6-TGN level monitoring may suffice for clinical practice.
Asunto(s)
Enfermedad de Crohn/sangre , Nucleótidos de Guanina/sangre , Inmunosupresores/farmacocinética , Tioguanina/farmacocinética , Tionucleótidos/sangre , Adulto , Enfermedad de Crohn/tratamiento farmacológico , Eritrocitos/metabolismo , Femenino , Humanos , Inmunosupresores/uso terapéutico , Masculino , Persona de Mediana Edad , Tioguanina/uso terapéuticoRESUMEN
The importance of methyl-thioIMP (Me-tIMP) formation for methylmercaptopurine ribonucleoside (Me-MPR) cytotoxicity was studied in Molt F4 cells. Cytotoxicity of Me-MPR is caused by Me-tIMP formation with concomitant inhibition of purine de novo synthesis. Inhibition of purine de novo synthesis resulted in decreased purine nucleotide levels and enhanced 5-phosphoribosyl-1-pyrophosphate (PRPP) levels, with concurrent increased pyrimidine nucleotide levels. The Me-tIMP concentration increased proportionally with the concentration of Me-MPR. High Me-tIMP concentration also caused inhibition of PRPP synthesis. Maximal accumulation of PRPP thus occurred at low Me-MPR concentrations. As little as 0.2 microM Me-MPR resulted already after 2 h in maximal inhibition of formation of adenine and guanine nucleotides, caused by inhibition of purine de novo synthesis by Me-tIMP. Under these circumstances increased intracellular PRPP concentrations could be demonstrated, resulting in increased levels of pyrimidine nucleotides. So, in Molt F4 cells, formation of Me-tIMP from Me-MPR results in cytotoxicity by inhibition of purine de novo synthesis.
Asunto(s)
Inosina Monofosfato/análogos & derivados , Mercaptopurina/análogos & derivados , Metiltioinosina/análogos & derivados , Linfocitos T/efectos de los fármacos , Tioinosina/análogos & derivados , Tionucleósidos/farmacología , Tionucleótidos/metabolismo , Tionucleótidos/farmacología , División Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Humanos , Mercaptopurina/metabolismo , Mercaptopurina/farmacología , Mercaptopurina/toxicidad , Metiltioinosina/metabolismo , Fosforribosil Pirofosfato/biosíntesis , Nucleótidos de Purina/metabolismo , Tionucleósidos/metabolismo , Células Tumorales Cultivadas/efectos de los fármacosRESUMEN
Aberrant DNA methylation can occur early in neoplastic transformation and may lead to the development of cancer. We describe the alterations of methylation patterns at the DNA sequence level which occurred in the 5' region of the calcitonin gene in lymphoblasts from 14 pediatric patients with acute lymphoblastic leukemia (ALL). The DNA methylation status of 25 CpG sites was determined by sequence analysis after bisulfite treatment of the DNA. This method showed that 13 out of 14 patients had increased numbers of methylated CpG sites in the calcitonin gene region at initial diagnosis when compared to control DNA from healthy individuals. The 5' region of the calcitonin gene appears to be methylated to a significantly higher degree in T lineage ALL compared to B lineage ALL (P < 0.01). Each of six ALL patients who were investigated at initial diagnosis and at relapse showed alterations in DNA methylation between the two stages. These six cases were also investigated by Southern blot analysis with methylcytosine-sensitive restriction enzymes and this method showed an increase in DNA methylation in only four of the six cases. The DNA sequencing method thus appears to be better suited to assess alterations of DNA methylation than Southern blot analysis. There are marked regional differences in the frequency of methylation of individual CpG sites and in the frequency of alterations between the two stages. Our results show that alterations in DNA methylation continue to occur from the initial stage to the relapse stage of ALL, suggesting that aberrant DNA methylation may play a role in tumor progression.
Asunto(s)
Calcitonina/genética , Metilación de ADN , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Secuencia de Bases , Southern Blotting , Humanos , Datos de Secuencia Molecular , RecurrenciaRESUMEN
Cytotoxicity of 6-mercaptopurine (6MP) and 6-methylmercaptopurine ribonucleoside (Me-MPR) was studied in Molt F4 human malignant lymphoblasts. Both drugs are converted into methylthioIMP (Me-tIMP), which inhibits purine de novo synthesis. Addition of amidoimidazole carboxamide ribonucleoside (AICAR) circumvented inhibition of purine de novo synthesis, and thus partly prevented 6MP and Me-MPR cytotoxicity. Purine nucleotides, and especially adenine nucleotides, were recovered by addition of AICAR. Under these conditions, Me-tIMP formation decreased. The results of this study indicate that formation of Me-tIMP may be important for 6MP cytotoxicity in Molt F4 cells. These data suggest that depletion of adenine nucleotides is the main cause for Me-tIMP cytotoxicity.
Asunto(s)
Aminoimidazol Carboxamida/análogos & derivados , Mercaptopurina/análogos & derivados , Mercaptopurina/antagonistas & inhibidores , Ribonucleósidos/farmacología , Tioinosina/análogos & derivados , Tionucleósidos/antagonistas & inhibidores , Células Tumorales Cultivadas/efectos de los fármacos , Nucleótidos de Adenina/metabolismo , Aminoimidazol Carboxamida/farmacología , Recuento de Células , Muerte Celular/efectos de los fármacos , Interacciones Farmacológicas , Nucleótidos de Guanina/metabolismo , Humanos , Metiltioinosina/análogos & derivados , Metiltioinosina/metabolismo , Tionucleótidos/metabolismo , Factores de TiempoRESUMEN
6-Methylmercaptopurine ribonucleoside-5'-phosphate (MeSPuRMP), the sole metabolite of 6-methylmercaptopurine ribonucleoside (MeSPuRib), is a strong inhibitor of purine de novo synthesis, inducing depletion of intracellular purine nucleotides and subsequent cell death in several tumor cell lines. In this study prevention of MeSPuRib cytotoxicity by compounds of the purine salvage pathway was studied in Molt F4 human malignant T-lymphoblasts. Adenosine, adenine and inosine were able to prevent depletion of the adenine nucleotide pool when used in combination with 0.5 microM MeSPuRib, but had virtually no effect on depletion of guanine nucleotides. Nevertheless, these three purine compounds were able to reduce the cytotoxic effects induced by MeSPuRib. Addition of guanosine to cells treated with 0.5 microM MeSPuRib normalized the guanine nucleotide pool, but adenine nucleotides remained depleted. Under these conditions, inhibition of cell growth was significantly decreased. With the combination of guanosine and 10 microM MeSPuRib, cytotoxicity was increased compared to 10 microM MeSPuRib alone, associated with a depletion of adenine nucleotides to 9% of untreated cells. Since cell growth and cell viability of Molt F4 cells are less inhibited by MeSPuRib under conditions where adenine nucleotide depletion is prevented by purine compounds (and where the other nucleotides are depleted) we conclude that depletion of adenine nucleotides is an important factor in MeSPuRib cytotoxicity.
Asunto(s)
Adenina/farmacología , Mercaptopurina/análogos & derivados , Metiltioinosina/antagonistas & inhibidores , Metiltioinosina/toxicidad , Nucleósidos de Purina/farmacología , Ribonucleósidos/antagonistas & inhibidores , Ribonucleósidos/toxicidad , Adenosina/farmacología , Antineoplásicos/toxicidad , División Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Guanosina/farmacología , Humanos , Inosina/farmacología , Mercaptopurina/antagonistas & inhibidores , Mercaptopurina/toxicidad , Nucleósidos/metabolismo , Nucleótidos/metabolismo , Linfocitos T/citología , Linfocitos T/efectos de los fármacos , Tioinosina/análogos & derivados , Tioinosina/toxicidad , Tionucleótidos/toxicidadRESUMEN
BACKGROUND: Thiopurine methyltransferase (TPMT) catalyses the S-methylation of 6-thiopurine drugs, which are commonly used in the treatment of autoimmune diseases, leukaemia and organ transplantation. TPMT activity is polymorphic as a result of gene mutations. Ethnic variations in phenotype and genotype have been identified in previous population studies, but no information was available within Latin-American populations. AIM: To establish the genetic polymorphism of TPMT in an Argentine population. METHODS: TPMT enzymatic activity of 147 healthy Argentine subjects was measured using a high-performance liquid chromatography method. The genotyping assay for nine defective alleles (TPMT*2 - *8) was based on restriction fragment length polymorphism polymerase chain reaction and allele-specific polymerase chain reaction methods. RESULTS: All subjects had detectable TPMT activity. Twelve individuals with low to intermediate activity were heterozygous for one of the mutant alleles: nine were TPMT*1/*3A, two TPMT*1/*2 and one TPMT*1/*4. All examined subjects with normal activity had wild-type genotype (TPMT*1/*1). CONCLUSION: Variant TPMT alleles were present in 8.2% of the examined subjects, which is in accordance with other studies. The frequency of TPMT*3A, TPMT*2 and TPMT*4 was 3.1%, 0.7% and 0.3%, respectively. TPMT*3A was the most prevalent allele, which is in accordance with results from Caucasian populations. This study provides the first analysis of TPMT activity and allele frequency distribution in Argentina, South America.
Asunto(s)
Metiltransferasas/genética , Polimorfismo Genético , Adolescente , Adulto , Anciano , Alelos , Argentina , Niño , Preescolar , Etnicidad/genética , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Metiltransferasas/metabolismo , Persona de Mediana EdadRESUMEN
The effects of inhibition of inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in guanine nucleotide de novo synthesis, on cell growth, cell viability, endogenous nucleotide concentrations and concentrations of extracellular nucleosides and bases were studied in Molt F4 human malignant lymphoblasts. Mycophenolic acid (MPA) was used as a specific inhibitor of the enzyme activity. IMPDH activity was maximally inhibited with 0.5 microM MPA. After a 2 h exposure of the cells to 0.5 microM MPA, guanine nucleotides were depleted to approximately 50% of control values, whereas 5-phosphoribosyl-1-pyrophosphate levels increased to approximately 200%. Under these conditions, cytotoxicity became obvious after 24 h. Depletion of guanine nucleotides and cytotoxicity were prevented by addition of guanosine to MPA treatment. Daily supplements of guanosine were required to prevent MPA cytotoxicity during the entire incubation period of 72 h. We conclude that depletion of guanine nucleotides, induced by treatment with MPA, induces a severe and rapid cytotoxicity in Molt F4 cells.
Asunto(s)
IMP Deshidrogenasa/antagonistas & inhibidores , Ácido Micofenólico/farmacología , Linfocitos T/enzimología , División Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Humanos , Nucleósidos/metabolismo , Nucleótidos de Purina/metabolismo , Nucleótidos de Pirimidina/metabolismo , Linfocitos T/citología , Linfocitos T/efectos de los fármacos , Células Tumorales CultivadasAsunto(s)
Errores Diagnósticos , Metiltransferasas/genética , Mutación , Alelos , Antimetabolitos Antineoplásicos/efectos adversos , Niño , Enzimas de Restricción del ADN/química , Frecuencia de los Genes , Genotipo , Humanos , Mercaptopurina/efectos adversos , Metiltransferasas/metabolismo , Reacción en Cadena de la Polimerasa/métodosAsunto(s)
Antimetabolitos Antineoplásicos/farmacología , Isoxazoles/farmacología , Tioguanina/farmacología , División Celular/efectos de los fármacos , Línea Celular , Supervivencia Celular/efectos de los fármacos , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Leucemia-Linfoma de Células T del Adulto , Leucemia-Linfoma Linfoblástico de Células Precursoras BAsunto(s)
Mercaptopurina/farmacología , Metotrexato/farmacología , Radioisótopos de Carbono , División Celular/efectos de los fármacos , Línea Celular , Ensayos de Selección de Medicamentos Antitumorales , Sinergismo Farmacológico , Glicina/metabolismo , Humanos , Cinética , Leucemia-Linfoma de Células T del Adulto , Fosfatos/metabolismo , Radioisótopos de Fósforo , Leucemia-Linfoma Linfoblástico de Células Precursoras B , Purinas/metabolismo , Tetrahidrofolato Deshidrogenasa/metabolismo , Timidina Monofosfato/metabolismoAsunto(s)
Antimetabolitos Antineoplásicos/efectos adversos , Médula Ósea/efectos de los fármacos , Mercaptopurina/efectos adversos , Metiltransferasas/metabolismo , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Antimetabolitos Antineoplásicos/uso terapéutico , Niño , Humanos , Mercaptopurina/uso terapéutico , Metiltransferasas/genética , Purinas/metabolismoAsunto(s)
Metiltransferasas/genética , Metiltransferasas/metabolismo , Leucemia-Linfoma Linfoblástico de Células Precursoras/enzimología , Alelos , Antimetabolitos Antineoplásicos/uso terapéutico , Niño , Femenino , Pruebas Genéticas , Genotipo , Humanos , Masculino , Mercaptopurina/uso terapéutico , Metotrexato/uso terapéutico , Mutación , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/genéticaRESUMEN
Treatment of MOLT F4 lymphoblasts with 6-mercaptopurine (6-MP) resulted in a decrease of ATP and a depletion of S-adenosylmethionine (AdoMet). To investigate whether this might affect the methylation of DNA, we treated MOLT F4 lymphoblasts with increasing concentrations of 6-MP, followed by labeling with [methyl-14C]methionine and [methyl-3H]thymidine. After DNA isolation, we measured the incorporated radioactivity and determined the 14C/3H ratio as a measure for the methylation of newly formed DNA. The 14C/3H ratio was decreased by 17% with 1 mumol/L 6-MP; treatment with increasing concentrations of 6-MP up to 10 mumol/L showed a further decrease to 70%, in comparison with untreated cells. To demonstrate that the methylation of deoxycytidine residues in DNA was reduced, we quantified hydrolyzed DNA by HPLC. The 14C/3H ratio showed a decrease with increasing 6-MP concentrations, indicating that treatment with 6-MP resulted in hypomethylation of DNA.
Asunto(s)
Metilación de ADN/efectos de los fármacos , ADN de Neoplasias/biosíntesis , Mercaptopurina/farmacología , Radioisótopos de Carbono , Humanos , Linfocitos , Metionina/metabolismo , Técnica de Dilución de Radioisótopos , Timidina/metabolismo , Tritio , Células Tumorales CultivadasRESUMEN
OBJECTIVE: To study the possible association of purine enzyme activities with response to azathioprine (AZA) treatment in rheumatoid arthritis (RA) and their correlation with parameters of disease activity. PATIENTS AND METHODS: Lymphocyte activities of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT), adenine phosphoribosyltransferase (APRT), purine nucleoside phosphorylase (PNP) and 5'-nucleotidase (5NT), and erythrocyte activities of thiopurine methyltransferase (TPMT) were measured in 14 healthy controls and 36 patients with RA. Eight patients had not previously been treated with AZA. Response to AZA therapy in 28 patients, determined in a prospective trial, was considered good in nine (group 1), insufficient in seven (group 2). In 12 patients AZA was withdrawn because of adverse reactions (group 3). Disease activity parameters were obtained simultaneously with purine enzyme measurements. Purine enzyme levels in the different groups were compared. RESULTS: Levels of 5NT activity were significantly lower in patients with RA than in healthy controls. PNP activity was higher in patients with RA not using prednisone compared with those who did and healthy controls. No clear correlation between purine enzyme levels and disease activity parameters was found. 5NT activities were significantly higher in group one than in group three (p = 0.012; alpha = 0.017), and almost significantly higher than in group two (p = 0.03; alpha = 0.017). CONCLUSIONS: The results indicate that purine enzyme activities in patients with RA differ from healthy controls, are associated with the outcome of AZA treatment and seem not to be associated with disease activity. Our findings may offer a clue to predict the response to AZA therapy in RA.
Asunto(s)
Artritis Reumatoide/tratamiento farmacológico , Artritis Reumatoide/enzimología , Azatioprina/uso terapéutico , Purinas/metabolismo , 5'-Nucleotidasa/sangre , Adenina Fosforribosiltransferasa/sangre , Adulto , Anciano , Femenino , Humanos , Hipoxantina Fosforribosiltransferasa/sangre , Masculino , Metiltransferasas/sangre , Persona de Mediana Edad , Proyectos Piloto , Purina-Nucleósido Fosforilasa/sangre , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
OBJECTIVE: Azathioprine (AZA) metabolism largely parallels the endogenous purine pathways. To date, thiopurine methyltransferase (TPMT) deficiency has been reported as a cause of AZA-related bone marrow toxicity in 1 patient with rheumatoid arthritis (RA). We therefore studied purine enzyme activities in 3 patients with RA who experienced AZA-related bone marrow toxicity. METHODS: Lymphocyte activity of purine nucleoside phosphorylase and 5'-nucleotidase (5NT) and erythrocyte activity of TPMT, key enzymes in thiopurine catabolism, were measured in 3 RA patients who had experienced AZA-related bone marrow toxicity and in 16 RA patients without signs of toxicity despite at least 6 months of treatment with AZA. RESULTS: Two patients with AZA-related bone marrow toxicity were found to have a TPMT deficiency, 1 partial and 1 total. In the third patient, 5NT activity was found to be well below the lowest level observed in the control subjects. CONCLUSION: All 3 patients with severe AZA-related bone marrow toxicity had abnormal purine enzyme activities. Deficiency of purine enzymes, including TPMT and 5NT, may be a cause of AZA-related bone marrow toxicity in patients with RA.
Asunto(s)
Artritis Reumatoide/tratamiento farmacológico , Artritis Reumatoide/enzimología , Azatioprina/efectos adversos , Azatioprina/toxicidad , Médula Ósea/efectos de los fármacos , 5'-Nucleotidasa/metabolismo , Femenino , Humanos , Hipoxantina Fosforribosiltransferasa/metabolismo , Masculino , Metiltransferasas/metabolismo , Persona de Mediana Edad , Purina-Nucleósido Fosforilasa/metabolismoRESUMEN
6-Mercaptopurine (6-MP) and methylmercaptopurine ribonucleoside (Me-MPR) are purine anti-metabolites which are both metabolized to methylthio-IMP (Me-tIMP), a strong inhibitor of purine synthesis de novo. Me-MPR is converted directly into Me-tIMP by adenosine kinase. 6-MP is converted into tIMP, and thereafter it is methylated to Me-tIMP by thiopurine methyltransferase, an S-adenosylmethionine (S-Ado-Met)-dependent conversion. S-Ado-Met is formed from methionine and ATP by methionine adenosyltransferase, and is a universal methyl donor, involved in methylation of several macromolecules, e.g. DNA and RNA. Therefore, depletion of S-Ado-Met could result in an altered methylation state of these macromolecules, thereby affecting their functionality, leading to dysregulation of cellular processes and cytotoxicity. In this study the effects of 6-MP and Me-MPR on S-Ado-Met, S-adenosylhomocysteine (S-Ado-Hcy), homocysteine and methionine concentrations are determined. Both drugs cause a decrease in intracellular S-Ado-Met concentrations and an increase in S-Ado-Hcy and methionine concentrations in Molt F4 human malignant lymphoblasts. The effects of both 6-MP and Me-MPR can be ascribed to a decreased conversion of methionine into S-Ado-Met, due to the ATP depletion induced by the inhibition of purine synthesis de novo by Me-tIMP. Both 6-MP and Me-MPR thus affect the methylation state of the cells, and this may result in dysregulation of cellular processes and may be an additional mechanism of cytotoxicity for 6-MP and Me-MPR.